.tb-container[data-toolset-blocks-container="8c13577c35fd68d7b70a2a5270dfdf0d"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-container[data-toolset-blocks-container="93f4094e2a5fc591c3cbd3f80a56f302"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 1px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] { text-align: center; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px -5px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__content { text-shadow: 5px 5px 10px rgba( 0, 0, 0, 0.5 );color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon { font-family: dashicons;margin-right: 10px; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon::before { content: '\f103'; } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="d8ee833869d806ba93519c93a0c99d68"] { border-top: 1px dotted rgba( 0, 0, 0, 1 );border-right: 0px dashed rgba( 0, 0, 0, 1 );border-bottom: 0px dashed rgba( 0, 0, 0, 1 );border-left: 0px dashed rgba( 0, 0, 0, 1 ); } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] { text-align: center; } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__icon { font-family: dashicons; } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] { text-align: center; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } @media only screen and (max-width: 599px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } 
Báo cáo thường niên năm 2019 của Abeona Therapeutics Inc
Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.
Báo cáo thường niên của Crescita Therapeutics Inc. năm 2019